Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Wave Life Sci Ord Sh (NQ: WVE )

5.750 -0.090 (-1.54%)
Streaming Delayed Price Updated: 9:49 AM EDT, Oct 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,213
Open 5.810
Bid (Size) 5.710 (2)
Ask (Size) 5.790 (2)
Prev. Close 5.840
Today's Range 5.716 - 5.895
52wk Range 3.040 - 7.120
Shares Outstanding 98,983,261
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire

Performance

YTD
-7.26%
-7.26%
1 Month
+29.21%
+29.21%
3 Month
+50.92%
+50.92%
6 Month
+29.21%
+29.21%
1 Year
+62.43%
+62.43%

More News

Read More
2 Cutting-Edge Gene-Editing Stocks That You Don't Want to Miss
Via The Motley Fool
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Earnings Scheduled For August 3, 2023
Via Benzinga
Analyst Ratings for WAVE Life Sciences
Via Benzinga
WAVE Life Sciences's Return On Capital Employed Overview
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
7 A-Rated Biotech Stocks for Your August Buy List
Via InvestorPlace
Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Recap: WAVE Life Sciences Q1 Earnings
Via Benzinga
Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Analyst Creates Bullish Pitch For WAVE Life Sciences, Says It Is 'Leader To Clinic In RNA Editing'
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023
Via Benzinga
Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Wave Life Sciences' Stock Falls: Investigational Therapy Fails To Show Clinical Benefit In Rare Neurological Diseases
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Estee Lauder, NerdWallet, Sprout Social And Other Big Stocks Moving Lower On Wednesday
Via Benzinga
Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.